[Skip to Content]
[Skip to Content Landing]
April 16, 1997

Management of Pharyngeal Carriers of Group A Streptococcal Organisms

Author Affiliations

The PeeDee Clinic Wilmington, NC
East Carolina University Greenville, NC

JAMA. 1997;277(15):1203-1204. doi:10.1001/jama.1997.03540390033030

To the Editor.  —Dr Cockerill and colleagues1 present interesting and relevant information that underscores an urgent need for the development of a consensus related to the management of the invasive streptococcal carrier state. As the authors point out, there is currently little agreement among physicians regarding the treatment of patients with asymptomatic streptococcal infection. In fact, some experts view this as a benign condition that poses no direct risk to patients or to their contacts and therefore requires no intervention.2 As a practical matter, we disagree with this passive posture. The study performed by Cockerill et al and common sense support the notion that eradication of this pathogen in the carrier state seems to serve the best interests of both the child and the community.During a recent outbreak of group A streptococcal disease, our clinic undertook a study that compared 2 currently accepted treatment options for eradication